HomeBiotechnologyargenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYV...
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia